Allergic Conjunctivitis (AC) - Market Insights, Epidemiology and Market Forecast-2027

Printer version

Send by email

Publication ID:

DEL0518006

Publication Date:

May 22, 2018

Pages:

118

Publisher:

Delveinsight

Countries:

Global

USD 6,250.00

Globally Trusted Brand

We help executives from Fortune 500 firms to Start-ups with their market research needs thus we can help you too.

If you have any pre-sales questions related to this report pelase let us know using the "Report Enquiry" form below. This will help us provide you with answers so that you can purchase with confidence.

Secure Checkout

You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.

Frequently Asked Questions

If you wish to read about frequently asked questions by our customers please visit our FAQs page.

Tabs

Description

Buy Specialized Pharma Market Research Report

Allergic Conjunctivitis (AC) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Allergic Conjunctivitis (AC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Allergic Conjunctivitis (AC) - Disease Understanding and Treatment Algorithm
The Allergic Conjunctivitis (AC) market report gives the thorough understanding of the Allergic Conjunctivitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Allergic Conjunctivitis in the US, Europe, and Japan.

Allergic Conjunctivitis Epidemiology
The Allergic Conjunctivitis (AC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed prevalent cases and sub-type specific prevalent cases) scenario of Allergic Conjunctivitis (AC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of diagnosed prevalent population of Allergic Conjunctivitis (AC) was found to be 64,945,428, in the year 2016.

Allergic Conjunctivitis Drug Chapters
This segment of the Allergic Conjunctivitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, there are mainly eight therapeutic classes of drugs contributing towards the market size of AC – Decongestants/Antihistamines, Corticosteroids, Topical Histamines, Systemic Histamines, Mast cell stabilizers (MCS), Immunomodulators, Nonsteroidal anti-inflammatory drugs (NSAIDs) and Dual acting Antihistamines/Mast cell stabilizers. The approved (and their generic versions) as well as off-label &/or OTC (Over the counter) products are being used for the treatment of Allergic Conjunctivitis, belonging to these therapeutic classes only. Detailed chapter for upcoming therapies like OTX-DP (also known as dexamethasone insert) (Ocular Therapeutics), ADX-102 (Aldeyra Therapeutics), PRT2761 (Portola Pharmaceuticals) and Bilastine (Faes Farma) have been covered in the report.

Allergic Conjunctivitis Market Outlook
The Allergic Conjunctivitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Upcoming therapies such as Zerviate (Nicox Pharma; NDA approved in May 2017, launch planned in the fall season of 2018), ADX-102 (Aldeyra Therapeutics), PRT-2761 (ORA, Inc.), OTX-DP (Ocular Therapeutix, Inc), DE114A (Santen Pharma; Only in Japan) and Bilastine (Faes Farma) have the potential to create a significant positive shift in the Allergic Conjunctivitis market size.
According to DelveInsight, the market of Allergic Conjunctivitis in 7MM was found to be USD 1,582 million in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Allergic Conjunctivitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Allergic Conjunctivitis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Allergic Conjunctivitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Allergic Conjunctivitis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This report will help to develop Business Strategies by understanding the trends shaping and driving Allergic Conjunctivitis market
• Organize sales and marketing efforts by identifying the best opportunities for Allergic Conjunctivitis market
• To understand the future market competition in the Allergic Conjunctivitis market.

These are on demand reports and will be delivered in 1 business days post placing the order.

Table of Contents

1. Key Insights
2. Allergic Conjunctivitis Market Overview at a Glance
2.1. Market Share (%) Distribution of Allergic Conjunctivitis in 2017
2.2. Market Share (%) Distribution of Allergic Conjunctivitis in 2027
3. Disease Background and Overview: Allergic Conjunctivitis (AC)
3.1. Introduction
3.2. Classification of Allergic Conjunctivitis
3.3. Causes
3.4. Risk factors
3.5. Symptoms
3.6. Pathophysiology
3.7. Diagnosis
4. Epidemiology and Patient Population
5. Key Findings
5.1. Population and Forecast Parameters
5.2. 7MM Total Diagnosed Prevalent Patient Population of Allergic Conjunctivitis
6. Country Wise-Epidemiology of Allergic Conjunctivitis
6.1. United States
6.1.1. Total Prevalent Patient Population of Allergic Conjunctivitis in the US
6.1.2. Sub-type Specific Prevalence of Allergic Conjunctivitis in the US
6.2. EU5 Countries
6.2.1. Germany
6.2.2. Total Prevalent Patient Population of Allergic Conjunctivitis in Germany
6.2.3. Sub-type Specific Prevalence of Allergic Conjunctivitis in Germany
6.2.4. France
6.2.5. Total Prevalent Patient Population of Allergic Conjunctivitis in France
6.2.6. Sub-type Specific Prevalence of Allergic Conjunctivitis in France
6.2.7. Italy
6.2.8. Total Prevalent Patient Population of Allergic Conjunctivitis in Italy
6.2.9. Sub-type Specific Prevalence of Allergic Conjunctivitis in Italy
6.2.10. Spain
6.2.11. Total Prevalent Patient Population of Allergic Conjunctivitis in Spain
6.2.12. Sub-type Specific Prevalence of Allergic Conjunctivitis in Spain
6.2.13. United Kingdom
6.2.14. Total Prevalent Patient Population of Allergic Conjunctivitis in the UK
6.2.15. Sub-type Specific Prevalence of Allergic Conjunctivitis in the UK
6.3. Japan
6.3.1. Total Prevalent Patient Population of Allergic Conjunctivitis in Japan
6.3.2. Sub-type Specific Prevalence of Allergic Conjunctivitis in the UK
7. Treatment Agorithm
7.1. American Guidelines on Allergic Conjunctivitis
7.2. European Guidelines: Treatment Algorithm for Allergic Conjunctivitis
7.3. Japanese Guidelines for Allergic Conjunctival diseases 2017
8. Unmet needs
9. Marketed Drugs
9.1. Marketed Drugs by Class
9.1.1. Decongestants/Antihistamines
9.1.2. Corticosteroids
9.1.3. Topical/Systemic antihistamines
9.1.4. Mast cell stabilizers
9.1.5. Non-steroidal anti-inflammatory disease (NSAIDs)
9.1.6. Immunomodulators
9.1.7. Dual acting Antihistamines/Mast cell stabilizers
10. Emerging Drugs
10.1. OTX-DP (Dexamethasone Insert): Ocular Therapeutics
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Regulatory Milestones
10.1.4. Clinical Development
10.1.5. Safety and Efficacy
10.1.6. Advantages and Disadvantages
10.2. ADX-102: Aldeyra Therapeutics
10.2.1. Drug Description
10.2.2. Product Profile
10.2.3. Regulatory Milestones
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Advantages and Disadvantages
10.3. PRT2761: Portola Pharmaceuticals
10.3.1. Drug Description
10.3.2. Product Profile
10.3.3. Regulatory Milestones
10.3.4. Clinical Development
10.3.5. Advantages and Disadvantages
10.4. Bilastine: FAES Farma
10.4.1. Drug Description
10.4.2. Product Profile
10.4.3. Regulatory Milestones
10.4.4. Clinical Development
10.4.5. Advantages and Disadvantages
11. Allergic Conjunctivitis: 7 Major Market Analysis
11.1. Market Size of Allergic Conjunctivitis in 7MM
12. Market Outlook by Country
13. The United States: Market Outlook
13.1. Total Market Size of Allergic Conjunctivitis
13.2. Allergic Conjunctivitis Market by Therapeutic Class
13.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market Size of Allergic Conjunctivitis
14.1.2. Allergic Conjunctivitis Market by Therapeutic Class
14.1.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.2. France
14.2.1. Total Market Size of Allergic Conjunctivitis
14.2.2. Allergic Conjunctivitis Market by Therapeutic Class
14.2.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.3. United Kingdom
14.3.1. Total Market Size of Allergic Conjunctivitis
14.3.2. Allergic Conjunctivitis Market by Therapeutic Class
14.3.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.4. Spain
14.4.1. Total Market Size of Allergic Conjunctivitis
14.4.2. Allergic Conjunctivitis Market by Therapeutic Class
14.4.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.5. Italy
14.5.1. Total Market Size of Allergic Conjunctivitis
14.5.2. Allergic Conjunctivitis Market by Therapeutic Class
14.5.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
15. Japan: Market Outlook
15.1. Total Market Size of Allergic Conjunctivitis
15.2. Allergic Conjunctivitis Market by Therapeutic Class
15.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
16. Market Drivers
17. Market Barriers
18. Appendix
19. Report Methodology
20. Capabilities
21. Disclaimer
22. About DelveInsight

List of Tables
Table 1: Characteristics of types of AC
Table 2: Risk factors for Allergic Conjunctivitis
Table 3: Clinical involvement of the ocular tissues in allergic eye disorders
Table 4: Grading of symptoms and severity (Based on ARIA Criteria)
Table 5: Total Prevalent Patient Population of Allergic Conjunctivitis in the 7MM (2016-2027)
Table 6: Total Prevalent Population of Allergic Conjunctivitis in the United States (2016-2027)
Table 7: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United States (2016-2027)
Table 8: Total Prevalent Population of Allergic Conjunctivitis in Germany (2016-2027)
Table 9: Sub-type Specific Prevalence of Allergic Conjunctivitis in Germany (2016-2027)
Table 10: Total Prevalent Population of Allergic Conjunctivitis in France (2016-2027)
Table 11: Sub-type Specific Prevalence of Allergic Conjunctivitis in France (2016-2027)
Table 12: Total Prevalent Population of Allergic Conjunctivitis in Italy (2016-2027)
Table 13: Sub-type Specific Prevalence of Allergic Conjunctivitis in Italy (2016-2027)
Table 14: Total Prevalent Population of Allergic Conjunctivitis in Spain (2016-2027)
Table 15: Sub-type Specific Prevalence of Allergic Conjunctivitis in Spain (2016-2027)
Table 16: Total Prevalent Population of Allergic Conjunctivitis in the UK (2016-2027)
Table 17: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United Kingdom (2016-2027)
Table 18: Total Prevalent Population of Allergic Conjunctivitis in Japan (2016-2027)
Table 19: Sub-type Specific Prevalence of Allergic Conjunctivitis in Japan (2016-2027)
Table 20: Algorithm for the management of seasonal allergic conjunctivitis
Table 21: American Guidelines for AC treatment
Table 22: Topical medications for Seasonal Allergic Conjunctivitis
Table 23: Treatment of Allergic Conjunctival diseases 2017
Table 24: Antiallergic eye drops, steroid eye drops and steroid ointments used in Allergic conjunctivitis in Japan
Table 25: OTX-DP, Clinical Trial Description, 2018
Table 26: ADX-102, Clinical Trial Description, 2018
Table 27: PRT2761, Clinical Trial Description, 2018
Table 28: Bilastine, Clinical Trial Description, 2018
Table 29: 7 Major Market Size of Allergic Conjunctivitis in USD Million (2016-2027)
Table 30: 7 Major Market Size of Allergic Conjunctivitis in USD Million (2016-2027)
Table 31: The U.S. Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 32: Emerging Therapies market size of Allergic Conjunctivitis in USD Million (2016-2027)
Table 33: Market Size of Allergic Conjunctivitis in Germany, in USD Million (2016-2027)
Table 34: Germany Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 35: Emerging Therapies market of Allergic Conjunctivitis in Germany, in USD Million (2016-2027)
Table 36: Market Size of Allergic Conjunctivitis in France, in USD Million (2016-2027)
Table 37: France Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 38: Emerging Therapies market of Allergic Conjunctivitis in France, in USD Million (2016-2027)
Table 39: Market Size of Allergic Conjunctivitis in the UK, in USD Million (2016-2027)
Table 40: UK Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 41: Emerging Therapies market of Allergic Conjunctivitis in the UK, in USD Million (2016-2027)
Table 42: Market Size of Allergic Conjunctivitis in Spain, in USD Million (2016-2027)
Table 43: Spain Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 44: Emerging Therapies market of Allergic Conjunctivitis in Spain, in USD Million (2016-2027)
Table 45: Market Size of Allergic Conjunctivitis in Italy, in USD Million (2016-2027)
Table 46: Italy Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 47: Emerging Therapies market of Allergic Conjunctivitis in Italy, in USD Million (2016-2027)
Table 48: Market Size of Allergic Conjunctivitis in Japan, in USD Million (2016-2027)
Table 49: Japan Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 50: Emerging Therapies market of Allergic Conjunctivitis in Japan, in USD Million (2016-2027)

List of Figures
Figure 1: Classification of Allergic Conjunctivitis
Figure 2: Symptoms of Allergic Conjunctivitis
Figure 3: The early and late phase of ocular allergic reactions
Figure 4: Total Diagnosed Prevalent Patient Population of Allergic Conjunctivitis in the 7MM (2016-2027)
Figure 5: Prevalence of Allergic Conjunctivitis in the United States (2016-2027)
Figure 6: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United States (2016-2027)
Figure 7: Total Prevalent Population of Allergic Conjunctivitis in Germany (2016-2027)
Figure 8: Sub-type Specific Prevalence of Allergic Conjunctivitis in Germany (2016-2027)
Figure 9: Total Prevalent Population of Allergic Conjunctivitis in France (2016-2027)
Figure 10: Sub-type Specific Prevalence of Allergic Conjunctivitis in France (2016-2027)
Figure 11: Total Prevalent Population of Allergic Conjunctivitis in Italy (2016-2027)
Figure 12: Sub-type Specific Prevalence of Allergic Conjunctivitis in Italy (2016-2027)
Figure 13: Total Prevalent Population of Allergic Conjunctivitis in Spain (2016-2027)
Figure 14: Sub-type Specific Prevalence of Allergic Conjunctivitis in Spain (2016-2027)
Figure 15: Total Prevalent Population of Allergic Conjunctivitis in the UK (2016-2027)
Figure 16: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United Kingdom (2016-2027)
Figure 17: Total Prevalent Population of Allergic Conjunctivitis in Japan (2016-2027)
Figure 18: Sub-type Specific Prevalence of Allergic Conjunctivitis in Japan (2016-2027)
Figure 19: Treatment of Allergic Conjunctivitis (AC): Proliferative (vernal keratoconjunctivitis)
Figure 20: Primary treatment of Acute and Chronic forms of Allergic conjunctivitis
Figure 21: Secondary treatment of Acute and Chronic forms of AC
Figure 22: Tertiary treatment of acute and chronic forms of ocular allergy
Figure 23: Treatment of Allergic Conjunctivitis (AC): Proliferative (vernal keratoconjunctivitis)
Figure 24: Unmet Needs of Allergic Conjunctivitis (AC)
Figure 25: 7 Major Market Size of Allergic Conjunctivitis in USD Million (2016-2027)
Figure 26: Market Size of Allergic Conjunctivitis in the United States, USD Millions (2016-2027)
Figure 27: The U.S. Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Figure 28: The U.S. Emerging Therapies market size of Allergic Conjunctivitis in USD Million (2016-2027)
Figure 29: Market Size of Allergic Conjunctivitis in Germany, USD Millions (2016-2027)
Figure 30: Allergic Conjunctivitis Market by Therapeutic Class in Germany, in USD Million (2016-2027)
Figure 31: Emerging Therapies market of Allergic Conjunctivitis in Germany, in USD Million (2016-2027)
Figure 32: Market Size of Allergic Conjunctivitis in France, USD Millions (2016-2027)
Figure 33: Allergic Conjunctivitis Market by Therapeutic Class in France, in USD Million (2016-2027)
Figure 34: Emerging Therapies market of Allergic Conjunctivitis in France, in USD Million (2016-2027)
Figure 35: Market Size of Allergic Conjunctivitis in the UK, USD Millions (2016-2027)
Figure 36: Allergic Conjunctivitis Market by Therapeutic Class in the UK, in USD Million (2016-2027)
Figure 37: Emerging Therapies market of Allergic Conjunctivitis in the UK, in USD Million (2016-2027)
Figure 38: Market Size of Allergic Conjunctivitis in Spain, USD Millions (2016-2027)
Figure 39: Allergic Conjunctivitis Market by Therapeutic Class in Spain, in USD Million (2016-2027)
Figure 40: Emerging Therapies market of Allergic Conjunctivitis in Spain, in USD Million (2016-2027)
Figure 41: Market Size of Allergic Conjunctivitis in Italy, USD Millions (2016-2027)
Figure 42: Allergic Conjunctivitis Market by Therapeutic Class in Italy, in USD Million (2016-2027)
Figure 43: Emerging Therapies market of Allergic Conjunctivitis in Italy, in USD Million (2016-2027)
Figure 44: Market Size of Allergic Conjunctivitis in Japan, USD Millions (2016-2027)
Figure 45: Allergic Conjunctivitis Market by Therapeutic Class in Japan, in USD Million (2016-2027)
Figure 46: Emerging Therapies market of Allergic Conjunctivitis in Japan, in USD Million (2016-2027)
Figure 47: Market Drivers
Figure 48: Market Barriers

Companies Covered

• Nicox Pharma • Allergan
• Aldeyra Therapeutics • Valeant
• ORA, Inc. • Novartis
• Ocular Therapeutix, Inc. • Pfizer
• Santen Pharma • Medpointe
• Faes Pharma • Bausche & Lombe

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Report Inquiry

Diseases

Research & Development (Pharma & Healthcare)

Drug Discovery

Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.

Related Market Research Reports

Publication	Price
Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027 Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Neuroblastoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.	USD 6,250.00
Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027 Herpes Simplex Virus (HSV) Infections - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HSV infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.	USD 6,250.00
Adrenoleukodystrophy (ALD) Market Insights, Epidemiology and Market Forecast - 2027 Adrenoleukodystrophy (ALD) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Adrenoleukodystrophy (ALD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.	USD 6,250.00
Spinal Muscular Atrophy (SMA) - Market Insight, Epidemiology and Market Forecast - 2027 Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Spinal Muscular Atrophy in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan.	USD 6,250.00
Narcolepsy- Market Insight, Epidemiology and Market Forecast - 2027 Narcolepsy - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Narcolepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.	USD 6,250.00
Pemphigus Vulgaris (PV) - Market Insights, Epidemiology and Market Forecast-2027 Pemphigus Vulgaris (PV) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Pemphigus Vulgaris (PV) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.	USD 6,250.00
Hepatitis D - Market Insights, Epidemiology and Market Forecast-2027 Hepatitis D - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatitis D in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom), Japan and China.	USD 6,250.00
Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2027 Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Renal Failure in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.	USD 6,250.00
Global Fabry Disease Market Research Report 2018 Fabry Disease Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).	USD 2,850.00
Global Fabry Disease Therapeutic Market Research Report 2018 Fabry Disease Therapeutic Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).	USD 2,850.00
Global Peripheral Vascular Disease Market – Focus on Technology (Stent, Drug-Coated Balloon, Atherectomy devices, Drug Eluting Stent (DES), PTA Balloon Catheter) Market Outlook 2022 Technological advancement in the global peripheral vascular disease market has led to development of technologies such as novel ‘3D’ stent system, specialty stent for PAD and advent of bioresorbable stent.	USD 1,100.00
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 Summary This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and also features data for dormant and discontinued projects.	USD 3,995.00

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

Contact Us

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

Latest Blog Posts

Stay Connected

Disclaimer: Market Research Reports, Inc. has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website MarketResearchReports.com only.

If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.